T. Butler and J. G. Gribben, Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia, Blood Rev, vol.24, pp.135-141, 2010.

R. Rosenquist, C. D. Bhoi, S. Mansouri, L. Gunnarsson, and R. , Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?, Leuk Lymphoma, vol.54, pp.2351-2364, 2013.

F. Van-bockstaele, B. Verhasselt, and J. Philippé, Prognostic markers in chronic lymphocytic leukemia: a comprehensive review, Blood Rev, vol.23, pp.25-47, 2009.

G. Fabbri, S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian et al., Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation, J Exp Med, vol.208, pp.1389-1401, 2011.

D. Rossi, A. Bruscaggin, V. Spina, S. Rasi, H. Khiabanian et al., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness, Blood, vol.118, pp.6904-6908, 2011.

D. Rossi, M. Fangazio, S. Rasi, T. Vaisitti, S. Monti et al., Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia, Blood, vol.119, pp.2854-2862, 2012.

D. Rossi, S. Rasi, V. Spina, A. Bruscaggin, S. Monti et al., Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia, Blood, vol.121, pp.1403-1412, 2013.

S. Jeromin, S. Weissmann, C. Haferlach, F. Dicker, K. Bayer et al., SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.28, pp.108-117, 2013.

D. A. Landau, S. L. Carter, P. Stojanov, A. Mckenna, K. Stevenson et al., Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, Cell, vol.152, pp.714-726, 2013.

S. P. Treon and . Xiii, Waldenströ m's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features, Hematol Oncol, vol.31, issue.1, pp.76-80, 2013.

H. Wang, Y. Chen, F. Li, K. Delasalle, J. Wang et al., Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study, Cancer, vol.118, pp.3793-3800, 2012.

S. P. Treon and Z. R. Hunter, A new era for Waldenstrom macroglobulinemia: MYD88 L265P, Blood, vol.121, pp.4434-4436, 2013.

N. Gachard, M. Parrens, I. Soubeyran, B. Petit, A. Marfak et al., IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenströ m macroglobulinemia/lymphoplasmacytic lymphomas, Leukemia, vol.27, pp.183-189, 2013.

G. A. Pangalis, M. Kyrtsonis, F. N. Kontopidou, M. P. Siakantaris, M. N. Dimopoulou et al., Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders, Clin Lymphoma, vol.5, pp.235-240, 2005.

M. L. Mcmaster and O. Landgren, Prevalence, clinical aspects, and natural history of IgM MGUS, Cytometry B Clin Cytom, vol.78, issue.1, pp.91-97, 2010.

R. A. Kyle, T. M. Therneau, S. V. Rajkumar, E. D. Remstein, J. R. Offord et al., Long-term follow-up of IgM monoclonal gammopathy of undetermined significance, Blood, vol.102, pp.3759-3764, 2003.

W. J. Chng, R. F. Schop, T. Price-troska, I. Ghobrial, N. Kay et al., Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma, Blood, vol.108, pp.2755-2763, 2006.

N. C. Gutié-rrez, E. M. Ocio, J. De-las-rivas, P. Maiso, M. Delgado et al., Gene expression profiling of B lymphocytes and plasma cells from Waldenströ m's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals, Leukemia, vol.21, pp.541-549, 2007.

A. Vardi, A. Agathangelidis, L. Sutton, M. Chatzouli, L. Scarfò et al., IgG-Switched CLL has a distinct immunogenetic signature from the common MD Variant: ontogenetic implications, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.323-330, 2014.

W. Xu, Y. Wang, F. L. Fang, C. Zhu, D. Wang et al., Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia, Leuk Res, vol.35, pp.1060-1065, 2011.

D. G. Oscier, J. Stevens, T. J. Hamblin, R. M. Pickering, R. Lambert et al., Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia, Br J Haematol, vol.76, pp.352-358, 1990.

J. Van-dongen, A. W. Langerak, M. Brü-ggemann, P. Evans, M. Hummel et al., Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, pp.2257-2317, 2003.

I. S. Lossos, A. A. Alizadeh, M. B. Eisen, W. C. Chan, P. O. Brown et al., Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas, Proc Natl Acad Sci, vol.97, pp.10209-10213, 2000.

H. Dö-hner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Krö-ber et al., Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, vol.343, pp.1910-1916, 2000.

C. Bastard, G. Raux, C. Fruchart, F. Parmentier, D. Vaur et al., Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients, Leukemia, vol.21, pp.1460-1463, 2007.

D. Rizzo, A. Lotay, N. Gachard, I. Marfak, J. Faucher et al., Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival, Am J Hematol, vol.88, pp.747-753, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00903796

G. Dighiero, P. Travade, S. Chevret, P. Fenaux, C. Chastang et al., B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL, Blood, vol.78, pp.1901-1914, 1991.

T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, vol.94, pp.1848-1854, 1999.

R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, pp.1840-1847, 1999.

N. Gachard, A. Salviat, C. Boutet, C. Arnoulet, F. Durrieu et al., Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method, Haematologica, vol.93, pp.215-223, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00451240

A. Victor-hoffbrand and T. J. Hamblin, Is ) leukemia * an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?, Leuk Res, vol.31, pp.273-275, 2007.

I. Del-giudice, F. R. Mauro, D. Propris, M. S. Santangelo, S. Marinelli et al., White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia, Haematologica, vol.96, pp.626-630, 2011.

A. Agathangelidis, N. Darzentas, A. Hadzidimitriou, X. Brochet, F. Murray et al., Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies, Blood, vol.119, pp.4467-4475, 2012.

J. C. Strefford, L. Sutton, P. Baliakas, A. Agathangelidis, J. Mal?íková et al., Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2, Leukemia, vol.27, pp.2196-2199, 2013.

P. Lin, S. Hao, B. C. Handy, C. E. Bueso-ramos, and L. J. Medeiros, Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients, Am J Clin Pathol, vol.123, pp.200-205, 2005.

L. Xu, Z. R. Hunter, G. Yang, Y. Zhou, Y. Cao et al., MYD88 L265P in Waldenströ m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allelespecific polymerase chain reaction, Blood, vol.121, pp.2051-2058, 2013.

C. Jiménez, E. Sebastián, G. P. Chilló-n-mc, M. Hernández, J. Escalante et al., MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenströ m's macroglobulinemia, Leukemia, vol.27, pp.1722-1728, 2013.

G. Pratt, S. Harding, R. Holder, C. Fegan, C. Pepper et al., Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia, Br J Haematol, vol.144, pp.217-222, 2009.

M. Hojjat-farsangi, M. Jeddi-tehrani, S. M. Razavi, R. A. Sharifian, H. Mellstedt et al., Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia, Cancer Sci, vol.100, pp.2346-2353, 2009.

D. Rossi, M. Cerri, D. Capello, C. Deambrogi, F. M. Rossi et al., Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome, Br J Haematol, vol.142, pp.202-215, 2008.

D. Rossi, V. Spina, R. Bomben, S. Rasi, M. Dal-bo et al., Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia, Blood, vol.121, pp.4902-4905, 2013.

S. Zibellini, D. Capello, F. Forconi, P. Marcatili, D. Rossi et al., Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma, Haematologica, vol.95, pp.1792-1796, 2010.

A. A. Warsame, H. Aasheim, K. Nustad, G. Trøen, A. Tierens et al., Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly-and self-reactive antibodies with similar reactivity, Blood, vol.118, pp.3331-3339, 2011.

V. Bikos, N. Darzentas, A. Hadzidimitriou, Z. Davis, S. Hockley et al., Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications, Leukemia, vol.26, pp.1638-1646, 2012.

D. Cortese, L. Sutton, N. Cahill, K. E. Smedby, C. Geisler et al., On the way towards a ) CLL prognostic index *: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort, Leukemia, vol.28, pp.710-713, 2013.

X. S. Puente, M. Pinyol, V. Quesada, L. Conde, G. R. Ordó-Ñ-ez et al., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, pp.101-105, 2011.

D. Ianni, M. Baldoni, S. Rosati, E. Ciurnelli, R. Cavalli et al., A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation, Br J Haematol, vol.146, pp.689-691, 2009.

P. Sportoletti, S. Baldoni, L. Cavalli, D. Papa, B. Bonifacio et al., NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL, Br J Haematol, vol.151, pp.404-406, 2010.

L. Wang, M. S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez et al., SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N Engl J Med, vol.365, pp.2497-2506, 2011.

N. Villamor, L. Conde, A. Martínez-trillos, M. Cazorla, A. Navarro et al., NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome, Leukemia, vol.27, pp.1100-1106, 2013.

V. Balatti, A. Bottoni, A. Palamarchuk, H. Alder, L. Z. Rassenti et al., NOTCH1 mutations in CLL associated with trisomy 12, Blood, vol.119, pp.329-331, 2012.

M. J. Maurer, J. R. Cerhan, J. A. Katzmann, B. K. Link, C. Allmer et al., Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia, Blood, vol.118, pp.2821-2826, 2011.

T. J. Hamblin, D. G. Oscier, J. R. Stevens, and J. L. Smith, Long survival in B-CLL correlates with surface IgM kappa phenotype, Br J Haematol, vol.66, pp.21-26, 1987.

C. C. Yin, P. Lin, D. A. Carney, B. C. Handy, G. Z. Rassidakis et al., Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein, Am J Clin Pathol, vol.123, pp.594-602, 2005.

L. Shvidel, T. Tadmor, A. Braester, O. Bairey, N. Rahimi-levene et al., Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group, Eur J Haematol, vol.93, pp.29-33, 2014.

C. Rozman and E. Montserrat, Viñ olas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance, Cancer, vol.61, pp.279-283, 1988.

R. Letestu, V. Lé-vy, V. Eclache, F. Baran-marszak, D. Vaur et al., Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters, Blood, vol.116, pp.4588-4590, 2010.

C. Codony, M. Crespo, P. Abrisqueta, E. Montserrat, and F. Bosch, Gene expression profiling in chronic lymphocytic leukaemia, Best Pract Res Clin Haematol, vol.22, pp.211-222, 2009.

A. D. Ramsay and M. Rodriguez-justo, Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy, Br J Haematol, vol.162, pp.15-24, 2013.

, ) IgM or IgG peaks in CLL are associated with short TFS D Rizzo et al